Issue Date: March 2, 2015
Sosei Acquires GPCR Firm Heptares
Japan’s Sosei Group has agreed to acquire London-based Heptares Therapeutics, a private company that develops small molecules and biologics targeting G protein-coupled receptors. Heptares shareholders score $180 million in cash and could get an additional $220 million in milestone payments. Sosei gains a pipeline of drugs to treat neurological and metabolic diseases and a structure-based drug design platform. Sosei says Heptares will position it for the loss of patent protection on two of its respiratory products marketed by Novartis.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society